PMID: 6967054Feb 15, 1980Paper

The generation of tumor heterogeneity in vivo

International Journal of Cancer. Journal International Du Cancer
D A Chow, A H Greenberg

Abstract

In order to determine whether host factors may contribute to the generation of tumor heterogeneity, the phenotypic stability of cells from a cloned tumor was examined during proliferation in tissue culture and in the syngeneic host. Growth of this cloned tumor was initiated both in vivo and in vitro, and the tumor populations were sampled at different time intervals by subcloning. The susceptibility of these tumor subclones to the cytotoxic action of natural antibodies and complement was used as a marker of their membrane phenotype. The extent of phenotypic variation of the clones in one sample was considered to be a measure of tumor heterogeneity. Following these procedures, we observed that a clone of the L5178Y murine lymphoma maintained its homogeneity during 5 months of in vitro culture. In contrast, a single passage of the same tumor clone for 3 1/2 weeks or 3 months in the syngeneic host resulted in the generation of a population of cells exhibiting a significant increase in heterogeneity. This relative instability of tumor phenotype in vivo suggests that the host milieu may allow the generation of tumor heterogeneity. Genetic or epigenetic mechanism(s) may be involved although the high frequency of new phenotypes argues...Continue Reading

References

Jan 1, 1977·Journal of Supramolecular Structure·S A Carlson, T D Gelehrter
Jun 15, 1979·International Journal of Cancer. Journal International Du Cancer·D A ChowA H Greenberg
Aug 11, 1977·Differentiation; Research in Biological Diversity·G Brunner
Jan 1, 1978·Advances in Cancer Research·I J FidlerI R Hart
Apr 15, 1979·International Journal of Cancer. Journal International Du Cancer·L B Wolosin, A H Greenberg
Oct 1, 1976·Science·P C Nowell
Nov 1, 1974·Proceedings of the National Academy of Sciences of the United States of America·L Mezger-Freed
Feb 1, 1973·Journal of the National Cancer Institute·R Hyman
Oct 1, 1973·Journal of Cellular Physiology·L A Chasin
Oct 1, 1971·Journal of Cellular Physiology·M Harris
Jan 1, 1971·Proceedings of the National Academy of Sciences of the United States of America·P Coffino, M D Scharff
Jun 18, 1966·Nature·J B Gurdon, V Uehlinger
Jun 24, 1967·Nature·G J Goldenberg, C E Thomas
Dec 1, 1958·Journal of Cellular Physiology. Supplement·G KLEIN, E KLEIN
Jul 15, 1958·Proceedings of the National Academy of Sciences of the United States of America·D L Nanney

❮ Previous
Next ❯

Citations

Mar 15, 1985·International Journal of Cancer. Journal International Du Cancer·G W Brown, D A Chow
Aug 15, 1985·International Journal of Cancer. Journal International Du Cancer·A CaignardF Martin
Apr 1, 1984·Clinical & Experimental Metastasis·G L Nicolson
Jan 1, 1983·Cancer Metastasis Reviews·G H Heppner, B E Miller
Dec 1, 1981·International Journal of Cancer. Journal International Du Cancer·A Neri, G L Nicolson
Jan 1, 1983·Cancer Metastasis Reviews·M W Kieran, B M Longenecker
Nov 15, 1983·International Journal of Cancer. Journal International Du Cancer·F MartinM Martin
Apr 14, 2011·Chemical Society Reviews·Maureen A Walling, Jason R E Shepard
Apr 15, 1984·International Journal of Cancer. Journal International Du Cancer·D A Chow
Jan 1, 1981·Journal of Supramolecular Structure and Cellular Biochemistry·J E TalmadgeD R Stanford
Jan 1, 1984·Cancer Metastasis Reviews·G L Nicolson
Jan 15, 1983·International Journal of Cancer. Journal International Du Cancer·D A ChowA H Greenberg
Jul 1, 1985·Clinical & Experimental Metastasis·D R Welch, S P Tomasovic
Apr 15, 1983·International Journal of Cancer. Journal International Du Cancer·M F Di RenzoP M Comoglio
Jan 1, 1981·International Journal of Cancer. Journal International Du Cancer·D A ChowA H Greenberg
Aug 31, 1981·Biochimica Et Biophysica Acta·I R Hart, I J Fidler
Jan 1, 1990·Molecular Aspects of Medicine·T N Dear, R F Kefford

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.